<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760578</url>
  </required_header>
  <id_info>
    <org_study_id>MSDC-C003</org_study_id>
    <nct_id>NCT00760578</nct_id>
  </id_info>
  <brief_title>A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator</brief_title>
  <official_title>A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metabolic Solutions Development Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metabolic Solutions Development Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type
      2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test</measure>
    <time_frame>28 days</time_frame>
    <description>Change from baseline of averaged postprandial glucose (mmol/L) in response to a Mixed-meal tolerance (MMT) test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Averaged Insulin Levels in Response to a Mixed-meal Tolerance Test</measure>
    <time_frame>After four weeks of active therapy</time_frame>
    <description>Change from baseline in averaged post prandial insulin levels in response to a mixed-meal tolerance test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FFAs</measure>
    <time_frame>After 28 days of active therapy</time_frame>
    <description>Change from baseline in Free Fatty Acids (FFAs)following 28 days of active therapy, as part of a lipid profile assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides</measure>
    <time_frame>28 days</time_frame>
    <description>Change compared to baseline in triglycerides following 28 days of active therapy, as part of a lipid profile assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL</measure>
    <time_frame>28 days</time_frame>
    <description>Change from baseline in HDL following 28 days of active therapy, as part of a lipid profile assessment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystaline cellulose once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 45 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0160 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSDC-0160 90 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDC-0160 220 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSDC-0160 220 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily, oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Once daily, oral</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0160 90 mg</intervention_name>
    <description>Once daily, oral</description>
    <arm_group_label>MSDC-0160 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0160 220 mg</intervention_name>
    <description>Once daily, oral</description>
    <arm_group_label>MSDC-0160 220 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 2 Diabetes naive or on metformin

          -  Male and female (postmenopausal or surgically sterilized), 18 to 70 years of age.

        Exclusion Criteria:

          -  Use of diabetes medications other than metformin.

          -  History of heart failure or previous myocardial infarction.

          -  Blood pressure great than 160/100 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R Colca, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Metabolic Solutions Development Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>March 19, 2013</results_first_submitted>
  <results_first_submitted_qc>March 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2013</results_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in the United States by 10 investigators between 26 Sep 2008 and 02 Feb 2009.</recruitment_details>
      <pre_assignment_details>This was a Ph 2A, double-blind, randomized, comparator- &amp; placebo-controlled study of Mitoglitazone in otherwise healthy adult patients with type 2 diabetes. The study consisted of a maximum 21-day screening period, a 2 week, single-blind, placebo lead-in period, a 4 week, double-blind treatment period and a 1 week posttreatment follow-up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MSDC-0160 90 mg</title>
          <description>MSDC-0160 90 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>MSDC-0160 220 mg</title>
          <description>MSDC-0160 220 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Pioglitazone</title>
          <description>Pioglitazone 45 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Microcrystaline cellulose once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Drug Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MSDC-0160 90 mg</title>
          <description>MSDC-0160 90 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>MSDC-0160 220 mg</title>
          <description>MSDC-0160 220 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Pioglitazone</title>
          <description>Pioglitazone 45 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Microcrystaline cellulose once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="8.20"/>
                    <measurement group_id="B2" value="53.7" spread="9.22"/>
                    <measurement group_id="B3" value="57.7" spread="6.38"/>
                    <measurement group_id="B4" value="54.5" spread="8.79"/>
                    <measurement group_id="B5" value="55.5" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test</title>
        <description>Change from baseline of averaged postprandial glucose (mmol/L) in response to a Mixed-meal tolerance (MMT) test.</description>
        <time_frame>28 days</time_frame>
        <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>Mitoglitazone 90 mg</title>
            <description>Mitoglitazone 90 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Mitoglitazone 220 mg</title>
            <description>Mitaglitazone 220 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo (microcrystalline cellulose) taken once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test</title>
          <description>Change from baseline of averaged postprandial glucose (mmol/L) in response to a Mixed-meal tolerance (MMT) test.</description>
          <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.349"/>
                    <measurement group_id="O2" value="-0.44" spread="0.358"/>
                    <measurement group_id="O3" value="-1.10" spread="0.390"/>
                    <measurement group_id="O4" value="0.51" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Averaged Insulin Levels in Response to a Mixed-meal Tolerance Test</title>
        <description>Change from baseline in averaged post prandial insulin levels in response to a mixed-meal tolerance test.</description>
        <time_frame>After four weeks of active therapy</time_frame>
        <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>Mitoglitazone 90 mg</title>
            <description>Mitoglitazone 90 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Mitoglitazone 220 mg</title>
            <description>Mitaglitazone 220 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Microcrystalline cellulose taken once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Averaged Insulin Levels in Response to a Mixed-meal Tolerance Test</title>
          <description>Change from baseline in averaged post prandial insulin levels in response to a mixed-meal tolerance test.</description>
          <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="4.664"/>
                    <measurement group_id="O2" value="-9.77" spread="4.785"/>
                    <measurement group_id="O3" value="-12.24" spread="5.215"/>
                    <measurement group_id="O4" value="-1.60" spread="4.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FFAs</title>
        <description>Change from baseline in Free Fatty Acids (FFAs)following 28 days of active therapy, as part of a lipid profile assessment</description>
        <time_frame>After 28 days of active therapy</time_frame>
        <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>Mitoglitazone 90 mg</title>
            <description>Mitoglitazone 90 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Mitoglitazone 220 mg</title>
            <description>Mitaglitazone 220 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg taken once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Microcrystalline cellulose taken once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FFAs</title>
          <description>Change from baseline in Free Fatty Acids (FFAs)following 28 days of active therapy, as part of a lipid profile assessment</description>
          <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.051"/>
                    <measurement group_id="O2" value="-0.15" spread="0.052"/>
                    <measurement group_id="O3" value="-0.19" spread="0.057"/>
                    <measurement group_id="O4" value="-0.01" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides</title>
        <description>Change compared to baseline in triglycerides following 28 days of active therapy, as part of a lipid profile assessment</description>
        <time_frame>28 days</time_frame>
        <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 90 mg</title>
            <description>MSDC-0160 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0160 220 mg</title>
            <description>MSDC-0160 220 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone</title>
            <description>Pioglitazone 45 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Microcrystaline cellulose once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides</title>
          <description>Change compared to baseline in triglycerides following 28 days of active therapy, as part of a lipid profile assessment</description>
          <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.160"/>
                    <measurement group_id="O2" value="-0.21" spread="0.164"/>
                    <measurement group_id="O3" value="-0.49" spread="0.179"/>
                    <measurement group_id="O4" value="0.15" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL</title>
        <description>Change from baseline in HDL following 28 days of active therapy, as part of a lipid profile assessment</description>
        <time_frame>28 days</time_frame>
        <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 90 mg</title>
            <description>MSDC-0160 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0160 220 mg</title>
            <description>MSDC-0160 220 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone</title>
            <description>Pioglitazone 45 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Microcrystaline cellulose once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL</title>
          <description>Change from baseline in HDL following 28 days of active therapy, as part of a lipid profile assessment</description>
          <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 averaged mixed-meal tolerance (MMT) test and laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.034"/>
                    <measurement group_id="O2" value="0.11" spread="0.034"/>
                    <measurement group_id="O3" value="0.09" spread="0.038"/>
                    <measurement group_id="O4" value="-0.03" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in FPG</title>
        <description>Change from baseline in fasting plasma glucose (FPG) following 28 days of active therapy</description>
        <time_frame>28 days</time_frame>
        <population>All patients who were compliant during the treatment period and who had Day 8 and Day 43 fasting plasma glucose values. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 90 mg</title>
            <description>MSDC-0160 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0160 220 mg</title>
            <description>MSDC-0160 220 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone</title>
            <description>Pioglitazone 45 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Microcrystaline cellulose once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG</title>
          <description>Change from baseline in fasting plasma glucose (FPG) following 28 days of active therapy</description>
          <population>All patients who were compliant during the treatment period and who had Day 8 and Day 43 fasting plasma glucose values. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.263"/>
                    <measurement group_id="O2" value="-0.97" spread="0.270"/>
                    <measurement group_id="O3" value="-1.38" spread="0.294"/>
                    <measurement group_id="O4" value="-0.04" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Insulin</title>
        <description>Change from Baseline in insulin levels following 28 days of active therapy</description>
        <time_frame>28 days</time_frame>
        <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 pre-dose laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 90 mg</title>
            <description>MSDC-0160 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>MSDC-0160 220 mg</title>
            <description>MSDC-0160 220 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone</title>
            <description>Pioglitazone 45 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Microcrystaline cellulose once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin</title>
          <description>Change from Baseline in insulin levels following 28 days of active therapy</description>
          <population>All patients who were compliant during the treatment period and who had a Day 8 and Day 43 pre-dose laboratory assessments. Compliance during the treatment period was determined by the sponsor through a manual review of pill counts, including a review of comments from the study sites.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.01" spread="1.820"/>
                    <measurement group_id="O2" value="-2.91" spread="1.867"/>
                    <measurement group_id="O3" value="-6.58" spread="2.034"/>
                    <measurement group_id="O4" value="-0.70" spread="1.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MSDC-0160 90 mg</title>
          <description>MSDC-0160 90 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Microcrystaline cellulose once daily</description>
        </group>
        <group group_id="E3">
          <title>Pioglitazone</title>
          <description>Pioglitazone 45 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>MSDC-0160 220 mg</title>
          <description>MSDC-0160 220 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry Colca, PhD</name_or_title>
      <organization>Metabolic Solutions Development Company</organization>
      <phone>269-343-6732</phone>
      <email>jcolca@msdrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

